TauRx’s product pipeline reflects the company’s unique approach to the treatment of Alzheimer’s and other neurodegenerative diseases. The company’s lead proprietary compound, LMTX®, has recently completed three Phase 3 clinical trials to evaluate its safety and efficacy in the treatment of Alzheimer’s disease and behavioural-variant frontotemporal dementia.

TauRx has also started a new clinical trial, named LUCIDITY. The trial uses FDG-PET imaging to examine the potential of its lead compound, LMTX®, in delaying the progression of disease pathology in the brain in patients with mild Alzheimer’s disease.

Several other compounds are also in early-stage development for the treatment of neurodegenerative diseases caused by protein aggregation.

Through TauRx’s technology platform, the company is continuing to discover and develop new treatments and diagnostic compounds.